Skip to main content
Full access
Reviews
Published Online: 18 July 2019

Complex Combination Pharmacotherapy for Bipolar Disorder: Knowing When Less Is More or More Is Better

Publication: FOCUS, A Journal of the American Psychiatric Association

Abstract

This overview presents the varied symptoms of psychopathology for which patients with bipolar disorder are prescribed medications so that practitioners can devise complementary, nonredundant, purposeful, and evidence-based regimens.

Abstract

Combination pharmacotherapy for bipolar disorder is commonplace and often reflects the severity and complexity of the illness and the comorbid conditions frequently associated with it. Across treatment settings, about one-fifth of patients with bipolar disorder appear to receive four or more psychotropic medications. Practice patterns often outpace the evidence-based literature, insofar as few systematic studies have examined the efficacy and safety of two or more medications for any given phase of illness. Most randomized trials of combination pharmacotherapy focus on the utility of pairing a mood stabilizer with a second-generation antipsychotic for prevention of either acute mania or relapse. In real-world practice, patients with bipolar disorder often take more elaborate combinations of mood stabilizers, antipsychotics, antidepressants, anxiolytics, stimulants, and other psychotropics for indefinite periods that do not necessarily arise purposefully and logically. In this article, I identify clinical factors associated with complex combination pharmacotherapy for patients with bipolar disorder; describe approaches to ensuring that each component of a treatment regimen has a defined role; discuss the elimination of unnecessary, ineffective, or redundant drugs in a regimen; and address complementary, safe, rationale-based drug combinations that target specific domains of psychopathology for which monotherapies often provide inadequate benefit.

Formats available

You can view the full content in the following formats:

Information & Authors

Information

Published In

Go to Focus
Go to Focus
FOCUS, A Journal of the American Psychiatric Association
Pages: 218 - 231

History

Published in print: Summer 2019
Published online: 18 July 2019

Keywords

  1. Mood Disorders-Bipolar
  2. Drug treatment/psychopharmacology

Authors

Affiliations

Joseph F. Goldberg, M.D. [email protected]
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City.

Notes

Send correspondence to Dr. Goldberg ([email protected]).

Funding Information

Dr. Goldberg is a consultant with Neurocrine, Lundbeck, Otsuka, Sunovion, and WebMD. He is with the speakers bureaus of Allergan, Neurocrine, Otsuka, Sunovion, and Takeda-Lundbeck and receives royalties from American Psychiatric Association Publishing.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Full Text

View Full Text

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Focus

PPV Articles - Focus

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share